Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 169Terminated 45Unknown 24Recruiting 21Active not recruiting 16Withdrawn 11Not yet recruiting 8No longer available 1Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Cytarabine 3venetoclax 2fludarabine 2olverembatinib 1ibrutinib 1fludarabine phosphate 1decitabine and cedazuridine drug combination 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Surveys and Questionnaires 1Ropivacaine 1Platelet Transfusion 1Melphalan 1Maintenance 1Magnetic Resonance Spectroscopy 1Leukapheresis 1Lenalidomide 1JNJ-64619178 1JNJ-64264681 1Inosine Monophosphate 1Imatinib Mesylate 1Dexamethasone 1Daunorubicin 1Cyclophosphamide 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Busulfan × Other hematologic neoplasm × Clear all
NCT05674539 2025-02-10

Reduced Intensity Conditioning Regimens for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 3 Enrolling by invitation
200 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡